

**Bowman, Diana M.; Hodge, Graeme A.** A big regulatory tool-box for a small technology. *NanoEthics* 2008 August; 2(2): 193-207. NRCBL: 5.4; 5.2; 5.3. SC: rv.

**Brownsword, Roger.** Regulating nanomedicine — the smallest of our concerns? *NanoEthics* 2008 April; 2(1): 73-86. NRCBL: 5.4; 5.3; 4.5; 5.2; 8.3.1.

**Cameron, Nigel M. de S.** Nanotechnology and the human future: policy, ethics, and risk. *Annals of the New York Academy of Sciences* 2006 December; 1093: 280-300. NRCBL: 5.4; 4.5; 5.2; 15.1; 1.3.11.

**Culliton, Barbara J.** Is special FDA regulation of nanomedicine needed? A conversation with Norris E. Alderson [interview]. *Health Affairs* 2008 March-June; 27(3-4): w315-w317. NRCBL: 5.4; 9.7; 5.3.

**Davies, J. Clarence.** Nanotechnology Oversight: An Agenda for the New Administration. Washington, DC: Project on Emerging Nanotechnologies, Woodrow Wilson International Center for Scholars, 2008 July: 28 p. NRCBL: 5.4; 1.3.5. Note: Supported by the Pew Charitable Trusts.

**Dupuy, Jean-Pierre; Grinbaum, Alexei.** Living with uncertainty: toward the ongoing normative assessment of nanotechnology. In: Schummer, Joachim; Baird, Davis, eds. *Nanotechnology Challenges: Implications for Philosophy, Ethics and Society*. Hackensack, NJ: World Scientific Pub., 2006: 287-334. NRCBL: 5.4; 5.3; 1.1.

**Ebbesen, Mette.** The role of the humanities and social sciences in nanotechnology research and development [See Erratum in: *NanoEthics* 2008 December; 2(3): 333]. *NanoEthics* 2008 April; 2(1): 1-13. NRCBL: 5.4; 5.3.

**Evans, Donald.** Ethics, nanotechnology and health. In: ten Have, Henk A.M.J., ed. *Nanotechnologies, Ethics and Politics*. Paris, France: UNESCO Pub., 2007: 125-153. 40 refs. NRCBL: 5.4; 9.1; 15.1; 15.3.

Keywords: \*nanotechnology; \*public health; \*risks and benefits; biomedical enhancement; brain; dehumanization; ecology; epidemiology; ethical analysis; genetic engineering; genetic information; genetic screening; health hazards; in vitro fertilization; mass screening; newborns; parental consent; patient care; population genetics; property rights; Proposed Keywords: clinical utility

**Evers, Johan; Aerts, Stefan; De Tavernier, Johan.** An ethical argument in favor of nano-enabled diagnostics in livestock disease control. *NanoEthics* 2008 August; 2(2): 163-178. NRCBL: 5.4; 22.3; 1.1.

**Florczyk, Stephen J.; Saha, Subrata.** Ethical issues in nanotechnology. *Journal of Long-term Effects of Medical Implants* 2007; 17(3): 271-280. NRCBL: 5.4.

**Glenn, Linda MacDonald; Boyce, Jeanann S.** Nanotechnology: considering the complex ethical, legal, and societal issues with the parameters of human perfor-

mance. *Nanoethics* 2008 December; 2(3): 265-275. NRCBL: 5.4; 4.5; 5.3.

**Godman, Marion.** But is it unique to nanotechnology? Reframing nanoethics. *Science and Engineering Ethics* 2008 September; 14(3): 391-403. NRCBL: 5.4; 5.2.

**Gordijn, Bert.** Ethical issues in nanomedicine. In: ten Have, Henk A.M.J., ed. *Nanotechnologies, Ethics and Politics*. Paris, France: UNESCO Pub., 2007: 99-123. NRCBL: 5.4; 9.5.1; 5.3; 5.2; 4.2.

**Greenwood, Mark.** Thinking big about things small: creating an effective oversight system for nanotechnology. Washington, DC: Project on Emerging Nanotechnologies, Woodrow Wilson International Center for Scholars, 2007 March: 30 p. NRCBL: 5.4; 5.2. Note: Supported by the Pew Charitable Trusts.

**Hassoun, Nicole.** Nanotechnology, enhancement, and human nature. *NanoEthics* 2008 December; 2(3): 289-304. NRCBL: 5.4; 1.1; 4.5; 16.1. SC: an.

**Holm, Søren.** Does nanotechnology require a new 'nanoethics'? In: Gunning, Jennifer; Holm, Søren, eds. *Ethics, Law and Society*. Volume III. Aldershot, Hants, England; Burlington, VT: Ashgate, 2007: 265-268. NRCBL: 5.4; 5.3; 1.3.9.

**Invernizzi, Noela.** Visions of Brazilian scientists on nanosciences and nanotechnologies. *NanoEthics* 2008 August; 2(2): 133-148. NRCBL: 5.4. SC: em.

**Joly, Pierre-Benoit; Kaufmann, Alain.** Lost in translation? The need for 'upstream engagement' with nanotechnology on trial. *Science as Culture* 2008 September; 17(3): 225-247. NRCBL: 5.4; 15.1; 1.3.11; 5.2; 5.3; 7.1. SC: le.

**Keiner, Suellen.** Room at the bottom? Potential state and local strategies for managing the risks and benefits of nanotechnology. Washington, DC: Woodrow Wilson International Center for Scholars, Project on Emerging Nanotechnologies, 2008 March: 52 p. NRCBL: 5.4; 1.3.5; 5.2.

**Khushf, George.** Importance of a midterm time horizon for addressing ethical issues integral to nanobiotechnology. *Journal of Long-term Effects of Medical Implants* 2007; 17(3): 263-269. NRCBL: 5.4; 15.1.

**Khushf, George.** Upstream ethics in nanomedicine: a call for research. *Nanomedicine* 2007 August; 2(4): 511-521. NRCBL: 5.4; 2.1; 15.1.

**Kuzma, Jennifer; Besley, John C.** Ethics of risk analysis and regulatory review: from bio- to nanotechnology. *NanoEthics* 2008 August; 2(2): 149-162. NRCBL: 5.4; 5.3; 5.2; 15.1; 1.3.11. SC: rv.

**Laurent, Louis; Petit, Jean-Claude.** Nanosciences and their convergence with other technologies: new golden age